

**From:** (b) (6)  
**Sent:** Tue, 25 Feb 2020 18:59:02 -0500  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** Fwd: Surfactant Protein-D against coronavirus

Please handle.

Begin forwarded message:

**From:** Marc Salzberg <(b) (6)>  
**Date:** February 25, 2020 at 4:42:47 PM EST  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>  
**Subject:** **Surfactant Protein-D against coronavirus**

Dear Dr. Fauci,

We are developing a recombinant human form of Surfactant Protein-D (AT-100), an endogenous collectin with strong immune-modulatory properties. AT-100 shows anti-inflammatory and anti-infectious properties. (b) (4)

(b) (4) There are data indicating that SP-D clears coronavirus (<https://www.ncbi.nlm.nih.gov/pubmed/19439011>). (b) (4)

While we are discussing this with a number of academic institutions, I was wondering, though, whether you and the NIH are interested to collaborate on evaluating AT-100 against coronavirus. Please let me know, if you are willing to schedule a phone call with our Chief Medical Officer Dr. Paul Kingma and I to discuss. There is obviously a sense of urgency behind this request.

Best regards,

Marc Salzberg

---

**Airway Therapeutics, Inc.**  
**Marc Salzberg, MD**  
President & CEO  
1200 Johnson Ferry Rd., Suite 300  
Marietta, GA 30068

Ph

(b) (6)